Endless Frontier Act

The Endless Frontier Act (HR6978) establishes a Directorate for Technology and Innovation in the National Science Foundation (NSF) and authorizes $100 billion over five years for research and development in key technology areas. These areas include artificial intelligence, quantum computing, advanced energy, advanced materials, and biotechnology. This bill directly addresses U.S. competitiveness in critical technologies against foreign adversaries, aiming to onshore manufacturing and innovation. The immediate impact is the creation of a dedicated funding mechanism for R&D, which will translate into grants and contracts for U.S. companies and academic institutions. The money trail for the Endless Frontier Act flows directly from the federal government, through the NSF's new directorate, to companies and research institutions. The primary mechanism will be R&D grants, cooperative agreements, and potentially direct procurement for specific projects. Companies positioned to capture these funds include semiconductor manufacturers like Intel ($INTC), NVIDIA ($NVDA), and Advanced Micro Devices ($AMD), which will benefit from investments in advanced computing and AI. Equipment suppliers like Applied Materials ($AMAT) and Lam Research ($LRCX) will see increased demand for their tools. Biotechnology companies such as Moderna ($MRNA), Pfizer ($PFE), and Eli Lilly ($LLY) will benefit from increased funding for biotechnology research, especially in areas like advanced therapeutics and biomanufacturing. Historical precedent for significant federal investment in technology R&D shows a direct market impact. For example, the CHIPS and Science Act, which built upon the principles of the Endless Frontier Act, passed in July 2022. Following its passage, Intel ($INTC) surged 8% in the subsequent week, and Taiwan Semiconductor Manufacturing Company ($TSM) gained 4% as the market priced in future subsidies and increased domestic demand for semiconductor manufacturing. Similarly, the initial funding for the Human Genome Project in the 1990s led to a boom in biotechnology research and the formation of numerous companies, driving significant growth in the sector over the following decades. This bill signals a similar long-term commitment to strategic technological advancement. Specific winners from this legislation include Intel ($INTC), NVIDIA ($NVDA), and Advanced Micro Devices ($AMD) due to their involvement in AI and advanced computing. Qualcomm ($QCOM) will benefit from investments in advanced wireless technologies. In the biotechnology sector, Moderna ($MRNA), Pfizer ($PFE), and Eli Lilly ($LLY) are poised to gain from increased R&D funding. Semiconductor equipment manufacturers like Applied Materials ($AMAT) and Lam Research ($LRCX) will see increased demand for their products as domestic manufacturing capacity expands. There are no clear losers identified at this stage, as the bill focuses on expanding domestic capabilities rather than restricting existing ones. The bill's referral to the House Committee on Science, Space, and Technology is the first step in the legislative process. While HR6978 did not pass in 2020, its core tenets were later incorporated into the CHIPS and Science Act, which became law in August 2022. This indicates strong bipartisan support for the underlying policy goals. Investors should monitor committee hearings and subsequent legislative actions, as the principles of this bill have already demonstrated their ability to be enacted into law, albeit in a modified form. The timeline for direct funding disbursements under similar legislation typically begins 6-12 months after enactment, as agencies establish grant programs and solicit proposals.